Evidence map›Paper›PMID 33106913›Full record

ArticleMolecular and cellular biochemistry2021

MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.

Chong Li, Shiyu Feng, Ling Chen

Open access · hybridAbstract read
In one paragraph

Article in Molecular and cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Transcriptomics analyses reveal the effects of Pentagamaboronon-0-ol on PI3K/Akt and cell cycle of HER2+ breast cancer cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Chong LiDepartment of Neurosurgery, Chinese PLA General Hospital, No. 28, Fuxing Rd, Haidian District, Beijing, 100853, China. kxya73y@163.com.ORCID http://orcid.org/0000-0001-9638-0770
Shiyu FengDepartment of Neurosurgery, Chinese PLA General Hospital, No. 28, Fuxing Rd, Haidian District, Beijing, 100853, China.
Ling ChenDepartment of Neurosurgery, Chinese PLA General Hospital, No. 28, Fuxing Rd, Haidian District, Beijing, 100853, China.
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have been widely reported to regulate the development and chemoresistance of a variety of tumors. Temozolomide (TMZ) is a first-line chemotherapy for treatment of glioma. However, the effect and the regulatory mechanism of lncRNA MSC-AS1 (MSC-AS1) in TMZ-resistant glioma remain unrevealed. Levels of MSC-AS1, microRNA-373-3p (miR-373-3p), and cytoplasmic polyadenylation element binding protein 4 (CPEB4) were determined by quantitative real-time polymerase chain reaction (qRT-PCR). All protein expression was detected by western blot. Cell viability and the half maximal inhibitory concentration (IC

Indexed as

AnimalsAntineoplastic Agents, AlkylatingApoptosisCell Line, TumorCell MovementCell ProliferationCentral Nervous System NeoplasmsComputational BiologyDatabases, GeneticDrug Resistance, NeoplasmFemaleGliomaHumansMaleMiceMice, NudeAKT1 protein, humanAntineoplastic Agents, AlkylatingCPEB4 protein, humanMicroRNAsMIRN373 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA-Binding ProteinsRNA, Long NoncodingTemozolomideCPEB4GliomamiR-373-3pMSC-AS1PI3K/AktTemozolomide

Identifiers

PMID33106913
PMCPMC7873112
OpenAlexW3094242096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.